Trained murine mesenchymal stem cells have anti-inflammatory effect on macrophages, but defective regulation on T-cell proliferation
PDA and BPC-157 share the exact same fifteen amino acids in the exact same order
Fibromyalgia and chronic fatigue: The underlying biology and related theoretical issues
announced that approximately 14 of 19 restricted peptides will return to legal compounding status: The announcement was made on the Joe Rogan Experience podcast on February 27, 2026 Peptides affected include BPC-157, Thymosin Alpha-1, AOD-9604, CJC-1295, Selank, Semax, KPV, MOTS-C, GHK-Cu, and others Moving from Category 2 to Category 1 allows licensed compounding pharmacies to legally prepare these peptides with a physicians prescription This does NOT mean these peptides are now FDA-approved drugs, which requires extensive clinical trials The legal basis was that the FDA lacked a required safety signal to justify the original ban Five peptides with weaker safety profiles may remain restricted Official FDA timeline is expected within weeks, though patients should monitor formal agency updates Patients should continue working with licensed physicians and accredited compounding pharmacies to ensure safe, quality-controlled access to peptide therapy
